Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.7K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

550
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
550
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

573
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
573
Subviral Agents01:29

Subviral Agents

580
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
580
Air-entraining Agents01:27

Air-entraining Agents

276
Air-entraining agents improve the durability and workability of concrete in climates with frequent freezing and thawing. These agents prevent cracks by introducing small air bubbles into the mix, creating spaces accommodating water expansion when temperatures drop. The air-entraining agents lower the surface tension of water, forming stable, small air bubbles. This method is more effective than having accidental large voids, as the intentional, smaller, and evenly distributed air voids improve...
276
Masking and Demasking Agents01:19

Masking and Demasking Agents

3.6K
EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The FUEL FALD Study: Effects of Udenafil on Liver Stiffness and Fibrosis after Fontan.

Pediatric cardiology·2026
Same author

The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants.

Circulation·2026
Same author

A Single-Center, Open-Label Study to Evaluate the Efficacy and Tolerability of Retinal Encapsulated in a Novel Biomimetic Exosome in the Treatment of Mild-To-Moderate Facial Photodamage.

Journal of cosmetic dermatology·2026
Same author

Injectable Use of Topical Cosmetics: A Medicolegal Cause for Concern.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2026
Same author

Clinical Characteristics Associated With Variability in Biopsy Grade Severity of Liver Fibrosis in Fontan Circulation.

JACC. Advances·2025
Same author

The Efficacy and Safety of Synchronous Parallel Ultrasound for the Clinical Improvement of Cellulite Using High-Density Handpiece.

Journal of cosmetic dermatology·2025

Related Experiment Video

Updated: Feb 9, 2026

Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease
04:11

Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease

Published on: April 28, 2023

2.6K

Expanding Treatment Options for Injectable Agents.

David J Goldberg1, Lawrence M Bass2, Rebecca Fitzgerald3

  • 1Department of Dermatology, Icahn School of Medicine at Mt. Sinai, New York, NY.

Aesthetic Surgery Journal
|June 14, 2018
PubMed
Summary
This summary is machine-generated.

Facial aging causes volume loss. Injectable fillers like calcium hydroxylapatite (CaHA), poly-L-lactic acid (PLLA), and hyaluronic acid (HA) can restore youthful appearance by addressing this loss and improving soft-tissue support.

More Related Videos

A New Best Practice for Validating Tail Vein Injections in Rat with Near-infrared-Labeled Agents
04:19

A New Best Practice for Validating Tail Vein Injections in Rat with Near-infrared-Labeled Agents

Published on: April 19, 2019

22.3K
Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
05:55

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

Published on: October 3, 2011

63.4K

Related Experiment Videos

Last Updated: Feb 9, 2026

Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease
04:11

Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease

Published on: April 28, 2023

2.6K
A New Best Practice for Validating Tail Vein Injections in Rat with Near-infrared-Labeled Agents
04:19

A New Best Practice for Validating Tail Vein Injections in Rat with Near-infrared-Labeled Agents

Published on: April 19, 2019

22.3K
Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
05:55

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

Published on: October 3, 2011

63.4K

Area of Science:

  • Aesthetic medicine and dermatology.
  • Biomaterials science.

Background:

  • Facial aging is characterized by loss of volume and soft-tissue support.
  • Restoring a youthful appearance involves correcting age-related volume deficits.

Purpose of the Study:

  • To discuss the versatility of calcium hydroxylapatite (CaHA) for facial volume replacement.
  • To outline the optimal applications and facial regions for CaHA, poly-L-lactic acid (PLLA), and hyaluronic acid (HA) fillers.

Main Methods:

  • Review of current literature on injectable facial fillers.
  • Discussion of the properties and clinical applications of CaHA, PLLA, and HA fillers.

Main Results:

  • CaHA demonstrates versatility in volume replacement and soft-tissue support.
  • Specific facial regions and aging concerns are best addressed by particular filler types (CaHA, PLLA, HA).

Conclusions:

  • Injectable fillers, including CaHA, PLLA, and HA, are effective for correcting age-related facial volume loss.
  • Understanding the distinct properties of each filler type allows for tailored treatment strategies to optimize aesthetic outcomes.